Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Ardelyx, Inc. ARDX

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
1.95
Total sells
4.30
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — 1 — — — — — — —
Sell — 6 — 1 9 1 1 9 2 1 8 —
Insider Ownership
3.48%

Capital & Financial Ratios

Market Cap
854.71
Revenue
450.89
Net Income
(55.70)
Free Cash Flow
(17.92)
Net Debt
(30.01)
Current Ratio
3.34
Debt/Equity
1.69
P/E ratio
0.00
P/S ratio
1.88
P/B ratio
5.69
Past 5Y EPS Growth
35.34%
This Y EPS Growth
29.55%
Next Y EPS Growth
241.81%
Next 5Y EPS Growth
30.00%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 184.30 250.10 264.69 281.83
Receivables 22.03 57.71 71.85 100.35
Inventory 12.45 21.17 17.74 25.86
Other — — — —
246.11 356.45 382.32 441.93
2023 2024 2025 Q'26
Payables 11.14 16.00 19.24 38.41
ST’ Debt — — — —
Other 15.04 34.64 47.58 70.96
50.39 77.83 88.61 132.22
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 94.47 120.88 — —
—
’25 74.11 97.66 110.33 125.22
407.32
’24 46.02 73.22 98.24 116.13
333.62
’23 11.37 22.33 56.39 34.36
124.46
’22 0.47 2.53 4.99 44.18
52.16
’21 6.58 1.31 1.17 1.03
10.10
’20 1.21 1.84 2.71 1.81
7.57
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (32.24) (6.40) — —
—
’25 (38.46) (25.34) 0.37 20.95
(42.48)
’24 (35.72) (19.40) 0.50 9.81
(44.81)
’23 (44.79) (14.74) (21.47) (8.72)
(89.72)
’22 (27.62) (31.28) (25.43) 14.28
(70.04)
’21 (44.22) (34.28) (34.59) (39.47)
(152.55)
’20 (24.95) (19.02) (19.88) (17.59)
(81.43)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (32.31) (6.41) — —
—
’25 (38.78) (25.99) 0.21 20.59
(43.97)
’24 (35.87) (19.53) 0.36 9.22
(45.82)
’23 (44.81) (14.83) (21.66) (8.76)
(90.06)
’22 (26.82) (30.81) (24.90) 14.23
(68.30)
’21 (44.99) (35.01) (35.03) (39.37)
(154.42)
’20 (24.97) (19.02) (19.93) (17.84)
(81.76)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.15) (0.07) — —
—
’25 (0.17) (0.08) 0.00 0.00
(0.26)
’24 (0.11) (0.07) 0.00 0.02
(0.17)
’23 (0.13) (0.08) 0.03 (0.12)
(0.30)
’22 (0.21) (0.19) (0.14) 0.06
(0.42)
’21 (0.34) (0.45) (0.42) (0.31)
(1.52)
’20 (0.25) (0.28) (0.20) (0.32)
(1.05)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.49 2.63 4.32 3.21 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.86 6.75 10.13 6.78 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 133 267 395 489 — — —
Employees
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 0.47 0.84 0.83 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.16 124.46 333.62 407.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 92.11% 85.70% 84.85% 90.29% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (67.20) (65.52) (38.87) (60.63) — — —
EBT
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (128.84%) (52.65%) (11.65%) (14.89%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (67.21) (66.07) (39.14) (61.60) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.14 1.29 2.06 3.06 — — —
Depreciation
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.33 0.57 1.42 1.69 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.42) (0.30) (0.17) (0.26) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.44) (0.41) (0.19) (0.18) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.00 0.00 (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.43) (0.41) (0.19) (0.18) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.62 0.76 0.74 0.69 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 158.69 219.33 235.23 241.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.15 10.66 3.57 3.45 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.33 7.95 6.88 8.42 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.62 9.62 3.29 3.31 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.05) (13.29) (23.96) (30.65) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (70.04) (89.72) (44.81) (42.48) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.74 (0.34) (1.01) (1.49) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (68.30) (90.06) (45.82) (43.97) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 88.00 195.72 278.62 293.71 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.82 49.82 150.85 202.83 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (80.09) (134.48) (99.25) (61.85) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 98.33 166.82 173.29 166.95 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (39.54%) (27.10%) (10.67%) (13.14%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (218.47%) (122.29%) (23.59%) (24.37%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.28%) (49.83%) (23.01%) (36.21%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Ardelyx, Inc. (ARDX) has achieved explosive revenue growth, surging from $2.6 million in 2018 to $334 million in 2024—a 150%+ CAGR over the last three years—driven by IBSRELA’s 2022 launch for IBS-C and XPHOZAH’s 2024 approval for hyperphosphatemia in CKD patients. This momentum correlates with a 360% employee headcount increase to 395 and revenue per employee jumping 620% to $845,000, while gross margins hold at 85-98% and losses narrow 75% to -$39 million EBT. Projections forecast revenue hitting $724 million by 2027 (33% CAGR), with profitability at $185 million net income, underscoring a maturing biotech playbook.

The balance sheet bolsters resilience, with $279 million working capital, a net cash position of -$99 million, and improving cash flows (OCF losses down 71%). Debt doubled to $151 million for commercialization, but valuation metrics shine: PS ratio at 3.6x (down from 90x), EV/Sales to 2.3x by 2027, and forward PE compressing to 9.7x. Stock volatility tracks revenue milestones, with analyst targets implying 111% average upside; recent director buys of $3.4 million signal confidence amid routine executive sells.

Yet risks loom—competition, 87% debt-to-equity, persistent negative FCF, and historical biotech pitfalls demand caution. If execution delivers 30-40% revenue CAGR and ROE turns double-digit by 2026-2027, ARDX could mirror mid-cap pharma successes; monitor Q1 2026 earnings for inflection confirmation.

Read full commentary →

Ardelyx, Inc. (ARDX) Latest News

News by impact score

Fine-tune

22 Aug

4 , 2:08 PM
Ardelyx cuts guidance citing payer hurdles, intensifying debate over fair value and pressuring near-term outlook. Guidance reduction from payer obstacles signals material operational and sentiment pressure likely to shift Ardelyx trajectory.

13 Aug

4 transcript www.fool.com, 8:44 PM
Ardelyx (ARDX) held its Q2 2026 earnings call to review financial results, operational updates, and outlook. Earnings call transcripts detail financial results and guidance that directly shape investor views and valuation.

10 Aug

3 , 8:19 PM
Ardelyx shares dropped 19.7% after the company raised IBSRELA revenue guidance and narrowed its losses. Raising revenue guidance and narrowing losses indicates improved financial performance with moderate effects on future trajectory.

7 Aug

4 , 11:13 AM
Ardelyx posts record revenue. Question arises if ARDX stock remains 70% undervalued. Record revenue directly improves financial performance outlook and raises investor focus on undervaluation potential.

4 transcript , 1:10 AM
Ardelyx Inc posted record Q2 2026 revenue of $118M driven by strong product sales. Record revenue signals major financial growth and stronger market position for Ardelyx.

6 Aug

3 , 7:10 PM
Ardelyx reports Q2 loss and misses revenue estimates. Q2 loss and revenue miss can pressure near-term stock price and sentiment.

3 , 7:00 PM
Ardelyx reported Q2 results with performance measured against analyst estimates on key metrics including revenue and EPS. Quarterly earnings versus estimates can shift near-term investor sentiment on financial trajectory.

3 www.marketbeat.com, 6:04 PM
Ardelyx Q2 earnings call highlighted revenue, product performance, pipeline updates and financial guidance. Q2 earnings details provide updates on financial health and operations that moderately influence market perception.

3 , 4:05 PM
Ardelyx reported second quarter 2026 financial results along with a business update. Quarterly financial results and business updates typically affect near-term investor sentiment and valuation without fundamentally reshaping long-term strategy.

30 Jul

3 , 10:00 AM
Ardelyx (ARDX) is scheduled to report earnings next week amid questions over possible negative results and implications for the stock. Upcoming earnings report may affect short-term stock price but does not alter long-term company trajectory.

29 Jul

3 , 10:46 AM
Access barriers continue to limit Xphozah uptake for Ardelyx based on combined physician, dietitian and patient chart data ahead of the TDAPA cliff. Ongoing access barriers to Xphozah point to constrained near-term adoption and revenue for Ardelyx.

20 Jul

3 , 3:18 PM
Claude AI indicates market overlooks Ardelyx (ARDX) growth catalysts. AI view on overlooked growth catalysts may moderately shift ARDX market sentiment.

26 Jun

4 stocktwits.com, 5:14 PM
Ardelyx's Xphozah loses final Medicare reimbursement battle, causing ARDX stock to tumble on blocked coverage for the drug. Denial of Medicare reimbursement for Xphozah blocks major revenue channel and damages Ardelyx long-term prospects.

23 Jun

4 Insider Monkey, 11:36 AM
Ardelyx sales growth accelerates on stronger product demand while pipeline candidates advance toward key regulatory milestones and potential launches. Sales momentum and pipeline progress represent core value drivers that can materially shift revenue trajectory and investor sentiment.

4 Jun

4 www.marketbeat.com, 8:04 AM
Ardelyx targets over $500 million in revenue from IBSRELA growth, positioning the company to reach profitability. Projected revenue above $500M from IBSRELA signals major growth and path to profitability for Ardelyx.

3 Jun

3 stocktwits.com, 7:52 PM
Ardelyx shares rise after hours on IBSRELA sales momentum and approaching profitability. IBSRELA momentum and near-term profitability signal improving revenue and earnings outlook.

30 May

3 Insider Monkey, 11:18 AM
Ardelyx (ARDX) stock receives investment evaluation based on its renal drug pipeline, recent regulatory milestones, financial position, and competitive market outlook. Opinion-based stock analysis can shift near-term investor sentiment around ARDX without changing underlying operations or long-term trajectory.

9 May

4 Simply Wall St., 11:11 AM
Ardelyx (ARDX) stock rose 10.3% after release of long-term safety data showing XPHOZAH's favorable profile in dialysis patients over extended periods, reinforcing its safety for chronic hyperphosphatemia treatment and driving positive investor sentiment. Long-term XPHOZAH safety data in dialysis patients triggered a 10.3% stock surge, significantly enhancing commercial prospects and market positioning.

7 May

4 GlobeNewswire, 8:01 AM
Ardelyx presented analysis at the National Kidney Foundation’s Spring Clinical Meetings supporting the long-term safety of XPHOZAH. Long-term safety data for XPHOZAH strengthens its adoption potential and investor sentiment in chronic kidney disease treatment.

3 Simply Wall St., 11:25 AM
Ardelyx (ARDX) reported Q1 2026 results and reaffirmed revenue guidance, leading to a reassessment of its valuation amid stable financial outlook. Q1 2026 results and reaffirmed revenue guidance moderately influence financial performance and investor sentiment without fundamentally altering trajectory.

2 May

3 Simply Wall St., 9:16 AM
Brokers updated analyst estimates for Ardelyx, Inc. (ARDX) following its first-quarter report. Analyst estimate revisions after Q1 report moderately influence financial performance expectations and market sentiment.

1 May

4 GuruFocus.com, 3:19 AM
Ardelyx Inc (ARDX) highlighted strong revenue growth and strategic investments in its Q1 2026 earnings call. Strong revenue growth signals improved financials, while strategic investments position ARDX for significant expansion and positive market sentiment.

30 Apr

4 app.moby.co, 8:15 PM
Ardelyx, Inc. (ARDX) released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings summary provides critical financial metrics and strategic outlook that can significantly sway ARDX stock performance and investor confidence.

4 transcript www.fool.com, 7:32 PM
Ardelyx (ARDX) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial metrics, product performance, and outlook directly influencing ARDX trajectory and investor sentiment.

4 www.marketbeat.com, 6:16 PM
Ardelyx released Q1 earnings call highlights covering financial results, IBSRELA and XPHOZAH updates, pipeline progress, and 2024 guidance. Q1 earnings highlights disclose revenue growth, product sales momentum, and reaffirmed guidance, driving significant positive shifts in market performance.

4 GlobeNewswire, 4:01 PM
Ardelyx, Inc. (ARDX) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates represent significant events that can drive substantial changes in ARDX stock price and investor perceptions.

3 , 6:25 PM
Ardelyx (ARDX) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite net loss affects financial performance and investor sentiment moderately.

3 Zacks, 6:00 PM
Ardelyx (ARDX) Q1 earnings key metrics compared to analyst estimates. Q1 earnings metrics versus estimates influence financial performance and investor sentiment.

23 Apr

3 Zacks, 10:00 AM
Ardelyx (ARDX) faces potential negative earnings report next week, with analysts highlighting key metrics like product sales, expenses, and cash position for investors to monitor. Anticipated negative earnings directly affect financial performance and short-term investor sentiment without fundamentally altering long-term trajectory.

4 Apr

3 Simply Wall St., 3:09 PM
Ardelyx, Inc. (ARDX) appoints new Chief Medical Officer, putting growth plans for tenapanor-based therapies to the test amid strategic scrutiny. CMO appointment influences key clinical and commercial execution for tenapanor's expansion but faces balancing market and operational factors.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us